D.A. Davidson & CO. Has $977,000 Position in Twist Bioscience Co. (NASDAQ:TWST)

D.A. Davidson & CO. increased its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 7.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,028 shares of the company’s stock after buying an additional 1,410 shares during the period. D.A. Davidson & CO.’s holdings in Twist Bioscience were worth $977,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. lifted its holdings in Twist Bioscience by 81.9% during the 4th quarter. Principal Financial Group Inc. now owns 374,551 shares of the company’s stock worth $17,405,000 after buying an additional 168,687 shares during the period. State of New Jersey Common Pension Fund D lifted its stake in shares of Twist Bioscience by 12.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 50,803 shares of the company’s stock worth $2,361,000 after acquiring an additional 5,701 shares during the period. Rhumbline Advisers boosted its holdings in Twist Bioscience by 2.6% in the fourth quarter. Rhumbline Advisers now owns 91,393 shares of the company’s stock valued at $4,247,000 after acquiring an additional 2,339 shares during the last quarter. Van ECK Associates Corp increased its position in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares during the period. Finally, Jennison Associates LLC raised its holdings in Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock worth $31,636,000 after purchasing an additional 302,884 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms have recently commented on TWST. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. TD Cowen reissued a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. JPMorgan Chase & Co. upped their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. Barclays set a $58.00 target price on Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. Finally, Robert W. Baird increased their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $54.40.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 2,216 shares of Twist Bioscience stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $52.70, for a total transaction of $116,783.20. Following the transaction, the chief executive officer now owns 674,718 shares of the company’s stock, valued at $35,557,638.60. This trade represents a 0.33 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam Laponis sold 5,886 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the transaction, the chief financial officer now directly owns 110,096 shares of the company’s stock, valued at approximately $4,762,752.96. This represents a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 37,180 shares of company stock worth $1,821,971. Corporate insiders own 3.01% of the company’s stock.

Twist Bioscience Trading Down 8.4 %

NASDAQ:TWST opened at $41.31 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The company has a market cap of $2.46 billion, a PE ratio of -12.22 and a beta of 1.87. The firm has a 50-day moving average of $48.10 and a 200-day moving average of $45.76.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.75) earnings per share. As a group, equities research analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.